Literature DB >> 23756490

Consensus on diagnosis and management of JME: From founder's observations to current trends.

Dorothée G A Kasteleijn-Nolst Trenité1, Bettina Schmitz, Dieter Janz, Antonio V Delgado-Escueta, Pierre Thomas, Edouard Hirsch, Holger Lerche, Carol Camfield, Betul Baykan, Martha Feucht, Iris E Martínez-Juárez, Reyna M Duron, Marco T Medina, Guido Rubboli, Judith Jerney, Bruce Hermann, Elza Yacubian, Michael Koutroumanidis, Ulrich Stephani, Javier Salas-Puig, Ronald C Reed, Friedrich Woermann, Britta Wandschneider, Michelle Bureau, Antonio Gambardella, Matthias J Koepp, Philippe Gelisse, Cardan Gurses, Arielle Crespel, Vi Huong Nguyen-Michel, Edoardo Ferlazzo, Thierry Grisar, Ingo Helbig, Bobby P C Koeleman, Pasquale Striano, Michael Trimble, Russel Buono, Patrick Cossette, Alfonso Represa, Charlotte Dravet, Anna Serafini, Ivanka Savic- Berglund, Sanjay M Sisodiya, Kazuhiro Yamakawa, Pierre Genton.   

Abstract

An international workshop on juvenile myoclonic epilepsy (JME) was conducted in Avignon, France in May 2011. During that workshop, a group of 45 experts on JME, together with one of the founding fathers of the syndrome of JME ("Janz syndrome"), Prof. Dr. Dieter Janz from Berlin, reached a consensus on diagnostic criteria and management of JME. The international experts on JME proposed two sets of criteria, which will be helpful for both clinical and scientific purposes. Class I criteria encompass myoclonic jerks without loss of consciousness exclusively occurring on or after awakening and associated with typical generalized epileptiform EEG abnormalities, with an age of onset between 10 and 25. Class II criteria allow the inclusion of myoclonic jerks predominantly occurring after awakening, generalized epileptiform EEG abnormalities with or without concomitant myoclonic jerks, and a greater time window for age at onset (6-25years). For both sets of criteria, patients should have a clear history of myoclonic jerks predominantly occurring after awakening and an EEG with generalized epileptiform discharges supporting a diagnosis of idiopathic generalized epilepsy. Patients with JME require special management because their epilepsy starts in the vulnerable period of adolescence and, accordingly, they have lifestyle issues that typically increase the likelihood of seizures (sleep deprivation, exposure to stroboscopic flashes in discos, alcohol intake, etc.) with poor adherence to antiepileptic drugs (AEDs). Results of an inventory of the different clinical management strategies are given. This article is part of a supplemental special issue entitled Juvenile Myoclonic Epilepsy: What is it Really?
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23756490     DOI: 10.1016/j.yebeh.2012.11.051

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  26 in total

Review 1.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

2.  Juvenile myoclonic epilepsy and Brugada type 1 ECG pattern associated with (a novel) plakophillin 2 mutation.

Authors:  Lorenzo Gigli; Giovanni Bertero; Monica Coll Vidal; Anna Iglesias; Oscar Campuzano; Pasquale Striano; Antonio Oliva; Ramon Brugada
Journal:  J Neurol       Date:  2017-02-20       Impact factor: 4.849

Review 3.  Childhood Electroclinical Syndromes: a diagnostic and therapeutic algorithm.

Authors:  Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2014-08-07       Impact factor: 1.967

4.  The Timing, Nature, and Range of Neurobehavioral Comorbidities in Juvenile Myoclonic Epilepsy.

Authors:  Dace N Almane; Jana E Jones; Taylor McMillan; Carl E Stafstrom; David A Hsu; Michael Seidenberg; Bruce P Hermann; Temitayo O Oyegbile
Journal:  Pediatr Neurol       Date:  2019-03-19       Impact factor: 3.372

5.  Generalized myoclonic epilepsy with photosensitivity in juvenile dogs caused by a defective DIRAS family GTPase 1.

Authors:  Franziska Wielaender; Riika Sarviaho; Fiona James; Marjo K Hytönen; Miguel A Cortez; Gerhard Kluger; Lotta L E Koskinen; Meharji Arumilli; Marion Kornberg; Andrea Bathen-Noethen; Andrea Tipold; Kai Rentmeister; Sofie F M Bhatti; Velia Hülsmeyer; Irene C Boettcher; Carina Tästensen; Thomas Flegel; Elisabeth Dietschi; Tosso Leeb; Kaspar Matiasek; Andrea Fischer; Hannes Lohi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

6.  Epidemiology and clinical manifestations of juvenile myoclonic epilepsy (JME) in Iran.

Authors:  Ali A Asadi-Pooya; Zabihollah Hashemzehi; Mehrdad Emami
Journal:  Neurol Sci       Date:  2014-12-05       Impact factor: 3.307

7.  Epilepsy in families: Age at onset is a familial trait, independent of syndrome.

Authors:  Colin A Ellis; Leonid Churilov; Michael P Epstein; Sharon X Xie; Susannah T Bellows; Ruth Ottman; Samuel F Berkovic
Journal:  Ann Neurol       Date:  2019-05-20       Impact factor: 10.422

8.  Neurodevelopment in new-onset juvenile myoclonic epilepsy over the first 2 years.

Authors:  Jack J Lin; Kevin Dabbs; Jeffrey D Riley; Jana E Jones; Daren C Jackson; David A Hsu; Carl E Stafstrom; Michael Seidenberg; Bruce P Hermann
Journal:  Ann Neurol       Date:  2014-08-18       Impact factor: 10.422

9.  DNA methylation of the BRD2 promoter is associated with juvenile myoclonic epilepsy in Caucasians.

Authors:  Shilpa Pathak; James Miller; Emily C Morris; William C L Stewart; David A Greenberg
Journal:  Epilepsia       Date:  2018-04-02       Impact factor: 5.864

Review 10.  Profile of brivaracetam and its potential in the treatment of epilepsy.

Authors:  Edoardo Ferlazzo; Emilio Russo; Laura Mumoli; Chiara Sueri; Sara Gasparini; Caterina Palleria; Angelo Labate; Antonio Gambardella; Giovambattista De Sarro; Umberto Aguglia
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-30       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.